INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC
Pomerantz LLP is investigating potential securities fraud claims against Teladoc Health, Inc. (NYSE: TDOC) on behalf of its investors. This investigation follows Teladoc's updated 2026 revenue guidance, which was significantly lowered due to "uncertainties inherent in cash pay and ongoing business model transition," and pressures on its BetterHelp platform. Following this announcement, Teladoc's stock price dropped by 38.32%.
Law firm probes Teladoc Health officers for possible shareholder rights breaches
Halper Sadeh LLC is investigating Teladoc Health (TDOC) officers and directors for potential breaches of fiduciary duties to shareholders, offering to handle claims on a contingent fee basis. This follows a previous securities fraud probe by Pomerantz LLP after Teladoc cut its 2026 revenue forecast, causing its stock to plunge. The law firm aims to improve corporate governance and recover funds for affected investors.
Teladoc Health (TDOC) Could Be 55% Undervalued On Board Change And 2026 Guidance
Teladoc Health (TDOC) is considered 55% undervalued by Simply Wall St, with a fair value of $15.00 against its current price of $6.81. This assessment follows the appointment of Mark V. Anquillare to its board and updated 2026 guidance, highlighting the company's cash generation, insurance-driven mental health model, and shift away from being solely a pandemic beneficiary. Despite recent share price pressure, the analysis suggests Teladoc's underlying financials are strong.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Teladoc Health, Inc. (TDOC) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teladoc Health, Inc. (TDOC) following a significant drop in its stock price. The investigation stems from Teladoc's second-quarter 2026 financial results, which missed analyst expectations, and its subsequent downward revision of full-year revenue guidance, particularly due to accelerated declines in cash pay users for its BetterHelp platform. Shareholders are encouraged to contact the firm to assist in the investigation.
Teladoc Health | 4: Statement of changes in beneficial ownership of securities-Officer Catapano Joseph Ronald
This document is a Statement of Changes in Beneficial Ownership of Securities, specifically Form 4, filed by Joseph Ronald Catapano, an officer at Teladoc Health. This filing indicates a change in his beneficial ownership of securities in the company.
Teladoc Health (TDOC) Could Be 55% Undervalued On Board Change And 2026 Guidance
Teladoc Health (TDOC) is considered 55% undervalued at its current share price of $6.81, with a fair value estimated at $15.00, according to Simply Wall St's analysis. This assessment follows the appointment of Mark V. Anquillare to its board and updated 2026 guidance. The company is highlighted as a cash-generative healthcare utility with significant cash reserves and a growing insurance-reimbursed mental health model, despite recent share price pressure.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Teladoc Health, Inc. (TDOC) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teladoc Health, Inc. (TDOC) following the company's Q2 2026 financial results, which reported lower-than-expected revenue and a reduced full-year guidance. The investigation focuses on potential claims for purchasers of Teladoc Health securities, especially after the stock price dropped significantly due to an accelerated decline in cash pay users and slower-than-expected insurance capacity expansion for its BetterHelp service. Investors are encouraged to seek more information about the investigation.
Teladoc Health (TDOC) Is Up 6.7% After Faster BetterHelp Insurance Shift Tightens 2026 Outlook
Teladoc Health's stock rose 6.7% following the acceleration of BetterHelp's nationwide insurance rollout, prompted by higher-than-expected insured demand. This shift, however, reduced the overall BetterHelp revenue outlook due to provider capacity constraints and a quicker move away from cash-pay users. The company's updated guidance for 2026 forecasts revenue between US$2.36 billion and US$2.45 billion, with a net loss of US$181 million to US$136 million, reflecting the ongoing challenge of balancing growth with profitability in the virtual care market.
Teladoc Health, Inc. (TDOC) Stock Analysis: Exploring a 16% Upside Potential Amidst Revenue Challenges
Teladoc Health (TDOC) is a leading virtual healthcare provider facing financial challenges despite its innovative role in the sector. The company has a market capitalization of $1.21 billion, with recent revenue decline and negative EPS, yet it maintains a healthy free cash flow. Analysts are cautiously optimistic, with an average target price suggesting a 16.21% upside, presenting a complex risk-reward profile for investors.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Teladoc Health, Inc. (TDOC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Teladoc Health, Inc. (NYSE: TDOC) investors. This investigation follows Teladoc's report of second-quarter 2026 financial results, which showed lower-than-expected revenue and a reduced full-year guidance, largely due to an accelerated decline in cash pay users for BetterHelp and slower-than-anticipated expansion of insurance capacity. The news led to a significant drop in Teladoc's stock price, prompting the firm to encourage affected investors to participate in their investigation.
Teladoc Health Inc (TDOC) Stock News Today
This article provides the current stock information for Teladoc Health Inc (TDOC), including its trading price, daily change, market capitalization, and a note that more news will be available soon. It highlights that the stock closed at 7.130 USD, up 6.74%, with a market cap of 1.29B. The page serves as a hub for news, analysis, and financial data for TDOC.
Teladoc Health (TDOC) Securities Investigation Notice - Levi & Korsinsky
Levi & Korsinsky has announced a securities investigation into Teladoc Health (TDOC) after its shares dropped over 28%. This plunge followed Teladoc's report of Q2 2026 revenue below consensus and a cut in its full-year 2026 revenue guidance. The investigation focuses on potential materially false or misleading statements regarding the company's financial outlook.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC
Pomerantz LLP is investigating potential claims on behalf of investors of Teladoc Health, Inc. (NYSE: TDOC) concerning alleged securities fraud or unlawful business practices. This investigation follows Teladoc's updated 2026 revenue guidance, which was significantly lowered due to "uncertainties inherent in cash pay and ongoing business model transition," causing a 38.32% drop in the company's stock price on July 30, 2026. Investors are encouraged to contact Pomerantz LLP for more information.
Bronstein, Gewirtz & Grossman, LLC Encourages Teladoc Health, Inc. (TDOC) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating Teladoc Health, Inc. (TDOC) on behalf of investors following a significant drop in its stock price. This drop occurred after Teladoc reported lower-than-expected Q2 2026 revenue and subsequently reduced its full-year 2026 revenue guidance. The firm cites an acceleration in the decline of cash pay users and slower-than-anticipated expansion in insurance capacity for Teladoc's BetterHelp service as key factors contributing to the financial shortfall.
Securities Fraud Investigation Into Teladoc Health Inc. (TDOC) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz has initiated a securities fraud investigation into Teladoc Health Inc. (TDOC) following a significant drop in its stock price. This investigation comes after Teladoc reduced its full-year revenue guidance and reported a more drastic reduction in BetterHelp's segment performance due to increased consumer movement towards insurance, provider capacity constraints, and a decline in cash pay users. Shareholders who lost money are encouraged to contact the firm to potentially pursue a claim.
Dimensional Fund Advisors LP Decreases Stake in Teladoc Health, Inc. $TDOC
Dimensional Fund Advisors LP significantly reduced its stake in Teladoc Health, Inc. by 16% in the first quarter, selling 1.2 million shares but still retaining over 6.3 million shares valued at approximately $34.3 million. Despite beating EPS estimates, Teladoc's revenue declined year-over-year and missed expectations. The company currently holds a consensus "Hold" rating from analysts, with a mixed outlook on price targets.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Teladoc Health, Inc. (TDOC) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teladoc Health, Inc. (TDOC) following the company's Q2 2026 financial results, which reported lower-than-expected revenue and a reduced full-year guidance. The investigation focuses on potential claims for investors who purchased Teladoc Health securities, especially after the stock price dropped significantly due to an accelerated decline in BetterHelp cash pay users and slower-than-anticipated insurance expansion. Investors are encouraged to contact the firm for more information.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Teladoc Health (TDOC)
Levi & Korsinsky is investigating Teladoc Health (NYSE: TDOC) on behalf of investors who lost money after the company reported lower-than-expected Q2 2026 revenue and cut its full-year guidance. Teladoc's stock fell almost 30% in a single session following the announcement of $606.9 million in revenue against consensus estimates of $615 million to $628 million, and a significant reduction in its full-year 2026 revenue outlook. Investors who purchased TDOC shares and suffered losses are encouraged to contact the firm for a no-cost review of their recovery options.
Teladoc Health (NYSE: TDOC) director Mark Anquillare submits initial Form 3
Teladoc Health Inc. (NYSE: TDOC) director Mark V. Anquillare has filed an initial Form 3, indicating his beneficial ownership of securities as a director. The filing reports no equity transactions and includes a reference to a Power of Attorney. This Form 3 establishes Anquillare's disclosure obligations for any future transactions in TDOC securities.
Teladoc Health | 4: Statement of changes in beneficial ownership of securities-Director Anquillare Mark V
This article reports a change in the beneficial ownership of securities for Mark V. Anquillare, a Director at Teladoc Health. The filing is a Statement of Changes in Beneficial Ownership, also known as a Form 4. This indicates that there has been a transaction involving Anquillare's holdings in the company.
Teladoc Health
This article provides an overview of Teladoc Health (TDOC), a company specializing in telehealthcare services. It details the company's profile, including its founding, headquarters, CEO, and employee count, alongside key financial statistics, stock price performance, and analyst consensus recommendations.
Director Mark V. Anquillare gets 37,425 RSUs at Teladoc Health (TDOC)
Teladoc Health director Mark V. Anquillare was granted 37,425 Restricted Stock Units (RSUs) on August 3, 2026. These RSUs, which represent a contingent right to one share of common stock each, will vest in a staggered manner: one-third on the first anniversary of the grant, and the remainder in eight equal quarterly installments thereafter. This award, valued at $0.00 per unit, results in Anquillare directly holding 37,425 RSUs following the transaction.
Teladoc Health (TDOC) On Weaker Earnings And Guidance The Fair Value Debate Returns
Teladoc Health (TDOC) is facing renewed scrutiny after reporting weaker Q2 revenue, a wider net loss, and reduced full-year guidance, leading to a significant stock pullback. Despite a narrative suggesting the stock is 55.5% undervalued with a fair value of $15.00 due to its cash generation and changing revenue mix, execution risks remain. Investors are encouraged to assess the underlying data and potential risks and opportunities beyond current headlines.
Teladoc Health, Inc. Announces Appointment of Mark V. Anquillare to its Board of Directors and on the Board?s Audit & Compensation Committees, Effective August 3, 2026
Teladoc Health, Inc. has announced the appointment of Mark V. Anquillare to its board of directors, effective August 3, 2026. Mr. Anquillare, former president and COO of Verisk Analytics, brings over 30 years of financial and executive leadership experience. He will serve on the board's Audit & Compensation committees and currently sits on the boards of Guidewire Software, RegEd, and Bamboo Insurance.
Teladoc Health | 8-K: Current report
This document is an 8-K current report filed by Teladoc Health. The content of the report itself is not provided in the input, only the document type.
Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors
Teladoc Health (NYSE: TDOC) has announced the appointment of financial executive Mark V. Anquillare to its board of directors. Mr. Anquillare, former president and chief operating officer of Verisk Analytics, will serve on the board’s Audit & Compensation committees, bringing over 30 years of financial and executive leadership experience. His expertise in data, technology, and AI within complex industries is expected to be invaluable as Teladoc Health continues its growth and transformation in virtual care.
TDOC SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Teladoc Health
SueWallSt is investigating potential securities law violations by Teladoc Health (TDOC) after the company cut its full-year 2026 revenue guidance, leading to a nearly 30% drop in stock value. The investigation focuses on whether Teladoc made false or misleading statements about its revenue outlook. Investors who suffered losses after purchasing TDOC shares are encouraged to contact SueWallSt for a free evaluation.
Are Investors Undervaluing Teladoc Health (TDOC) Right Now?
The article analyzes why Teladoc Health (TDOC) might be undervalued, highlighting its Zacks Rank #2 (Buy) and an "A" grade for Value. It uses metrics like P/B, P/S, and P/CF ratios to demonstrate that TDOC's valuation is attractive compared to its industry averages. The strong earnings outlook further supports the idea that TDOC is an impressive value stock.
Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors
Teladoc Health has announced the appointment of financial executive Mark V. Anquillare to its board of directors. Anquillare, former president and COO of Verisk Analytics, will serve on the board's Audit & Compensation committees, bringing over 30 years of experience in finance and leadership to the virtual care company. His expertise in data analytics and guiding public companies through growth will be valuable as Teladoc Health continues to innovate in the healthcare sector.
Teladoc Health: Insurance Demand Outpaces Provider Capacity As BetterHelp Revenue Falls 12%
Teladoc Health's BetterHelp division experienced a significant shift towards insurance-covered therapy, leading to a 12% revenue decline as increased demand outpaced provider capacity and could not offset a sharp drop in cash-pay customers. While insurance-covered services saw over a tenfold revenue increase, the transition severely impacted BetterHelp's profitability, with adjusted EBITDA plunging 96%. Teladoc is accelerating its insurance rollout but faces challenges in scaling provider capacity and adapting to the operational requirements of insurance-based services.
Teladoc Health (TDOC) Is Down 23.5% After Weak Q2 And Lower 2026 Guidance Has The Bull Case Changed?
Teladoc Health (TDOC) reported a challenging Q2 2026 with declining sales, a wider net loss, and lowered full-year 2026 guidance, primarily due to struggles in its BetterHelp mental health unit as users shift to insurance-covered care. This performance pressures the company's investment narrative, which relies on the scalability and profitability of virtual care, and raises questions about its projected revenue and earnings growth. The revised guidance, forecasting lower revenue and continued losses, underscores the risks associated with the transition away from cash-pay models.
Teladoc Health Number of Employees 2026 | Employee Count & Headcount Data
Teladoc Health (TDOC) had 5,704 employees worldwide as of March 2026, marking a 1.7% decline from 2023 but a recovery from a low in 2025. The company is actively hiring with 611 job postings in 2026, and its workforce is primarily concentrated in the United States, with Germany being its fastest-growing location. Employee sentiment is negative and declining, and the average salary is $102,013 globally.
Teladoc Health Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Teladoc Health (TDOC)
Levi & Korsinsky, LLP has announced an investigation into Teladoc Health (TDOC) after the company's stock dropped over 28% following a disappointing Q2 2026 earnings report and reduced full-year revenue guidance. The investigation focuses on whether Teladoc made false or misleading statements regarding its revenue figures and guidance, particularly concerning its BetterHelp division. Investors who suffered losses after purchasing TDOC shares are encouraged to contact Levi & Korsinsky for a free evaluation.
Teladoc Health (TDOC) Could Be 56% Undervalued As Weak Results Reset Expectations
Teladoc Health (TDOC) shares have seen a significant drop after reporting weaker-than-expected Q2 2026 results and revised guidance. Despite recent poor performance, one valuation narrative suggests TDOC could be 56% undervalued with a fair value of $15.00, driven by potential success in its BetterHelp insurance pivot and free cash flow durability. However, the company still faces risks from underperforming its insurance pivot or increased competition in the telehealth market.
Teladoc Health (TDOC) Stock Price Cracks As BetterHelp Reset Deepens
Teladoc Health's stock price dropped over 28% after its Q2 2026 earnings report, largely due to a "reset" in its BetterHelp segment. While Integrated Care showed some positive signs, BetterHelp experienced an 11.6% revenue decline and near break-even EBITDA as it transitions from cash pay to insurance-based growth. This shift raises concerns about margin pressure and long-term monetization for the company.
Teladoc Health | 10-Q: Q2 2026 Earnings Report
This article provides details about Teladoc Health's 10-Q filing for the second quarter of 2026. The 10-Q is a comprehensive quarterly financial report submitted to the SEC, offering insights into the company's performance, financial condition, and operational developments. As of the time of publication, the report had not yet been released.
Teladoc lowers revenue outlook amid BetterHelp demand headwinds
Teladoc Health has lowered its full-year revenue outlook by 5% due to significant challenges at its mental health unit, BetterHelp. The segment experienced unexpectedly high consumer demand for its insurance offering, which it struggled to meet, causing a faster-than-anticipated decline in its cash-pay business. Despite expanding insurance options and credentialing more providers, BetterHelp's capacity could not convert increased demand into higher revenue, leading to a 12% year-over-year decrease in its topline for the second quarter.
Teladoc Health (TDOC) Stock Looks Cheap Even As The Market Stays Cautious
Teladoc Health (TDOC) stock appears undervalued despite a significant 93.9% decline over the past five years. Both a Discounted Cash Flow (DCF) model and Price/Sales (P/S) ratio analysis suggest the stock is cheap compared to its intrinsic value and industry peers. The company's new "Teladoc One" virtual care model is a key factor, though its limited rollout this year and broader availability in 2027 contribute to market caution.
Teladoc Health trims 2026 revenue forecast amid challenges with BetterHelp insurance shift
Teladoc Health has lowered its 2026 revenue forecast due to unexpected pressure on its BetterHelp virtual behavioral health unit. The company is transitioning BetterHelp from a cash-pay to an insurance-covered model, but consumer demand for insurance-based services is outpacing clinical capacity, leading to a faster-than-anticipated decline in cash-pay revenue. Despite the challenges, Teladoc's integrated care segment is showing steady growth, and the company is focused on strategic actions to stabilize the business and improve long-term performance.
Teladoc Stock Plummets on Revenue Miss, Lowered Outlook
Teladoc Health Inc (NYSE:TDOC) saw its shares plunge by 22% after reporting second-quarter revenues that missed Wall Street estimates and subsequently lowering its full-year guidance. Despite a smaller-than-expected loss per share, investors reacted negatively to slowing growth in its BetterHelp mental health segment. The stock is facing its worst day in over two years, landing on the short sell restricted list.
Teladoc Health Q2 Loss Widens, Revenue Falls; 2026 Guidance Updated
Teladoc Health Inc. reported a widening loss and a decrease in revenue for its second quarter of 2026, compelling the company to update its full-year 2026 guidance. This financial performance has led to a tumble in Teladoc's stock, primarily due to shifts in demand affecting its BetterHelp segment. The article notes that the full content is reserved for members.
Teladoc Health sinks 21% after mixed quarter and soft outlook (TDOC:NYSE)
Teladoc Health (TDOC) shares dropped 21% in premarket trading after reporting a mixed quarterly performance and issuing a Q3 outlook that missed Wall Street expectations. The company's CEO, Charles Divita, indicated that advertising spending for 2026 is now expected to be lower than previously anticipated.
Teladoc Health, Inc. Stock 12‑Month Price Target Raised to $7.84, Implies 15% Downside
Teladoc Health, Inc.'s average 12-month price target has modestly increased to $7.84 from $7.76, based on estimates from 19 analysts, with a range of $5 to $11. This updated target suggests a potential 15% downside from its July 29 closing price. The consensus rating for TDOC remains "Hold" across 25 analysts.
Teladoc Leans Toward Insurance-Pay as Larger Part of Revenue Mix, Driven by BetterHelp
Teladoc (NYSE: TDOC) is shifting its BetterHelp revenue mix towards insurance-pay as consumer demand for insurance-covered mental health services outpaces clinician capacity in some markets, leading to a decline in cash-pay revenue. This shift resulted in a 5% reduction in Teladoc's consolidated revenue guidance for the year. To address these challenges, BetterHelp has accelerated its nationwide insurance rollout, credentialed over 8,000 providers, and is refining its marketing strategy to align with increased insurance demand and available provider capacity.
Teladoc Health | 8-K: Teladoc Health Reports Second Quarter 2026 Results
This document indicates that Teladoc Health has filed an 8-K report with the SEC. The report details the company's financial results for the second quarter of 2026. Further specific financial data would be found within the 8-K filing itself.
Teladoc Health (TDOC) Stock Still Looks Undervalued After a 94% Five Year Fall
Teladoc Health (TDOC) stock appears undervalued despite a significant 94% decline over the past five years. Both Discounted Cash Flow (DCF) analysis and market multiples suggest upside potential, with the DCF model indicating a 37.0% discount to intrinsic value. The company's future hinges on the successful rollout of its Teladoc One virtual care model, which carries execution risks that the market may be cautiously pricing in.
Teladoc Health (TDOC) Releases Q2 2026 Earnings: Revenue Misses Estimates but EPS Improves
Teladoc Health (TDOC) reported Q2 2026 revenue of $606.9 million, missing estimates, while its net loss of $(0.21) per diluted share improved compared to the prior year and beat estimates. The company's financials also detail insider trading activity with 18 sales and no purchases in the last 6 months, and notable hedge fund activity with significant additions and removals of shares. Analyst price targets for TDOC average around $7.0.
Teladoc Health Launches Person-Centered Virtual Care Platform for Connected Care
Teladoc Health has introduced Teladoc One, a new virtual care platform focused on personalized, coordinated healthcare by integrating primary, chronic disease, mental health, and acute care. The platform uses its Pulse intelligence engine to unify patient data, enabling multidisciplinary care teams and an AI assistant to identify risks, coordinate interventions, and ensure continuity of care. Teladoc Health plans to tie its compensation to performance, beginning with cardiometabolic conditions, with a rollout starting in September 2026.
Teladoc Health Canada achieves Accreditation Canada Primer Award
Teladoc Health Canada has received the Accreditation Canada Primer Award, validating its dedication to providing safe, high-quality, and patient-centered virtual and hybrid care. This achievement marks a significant milestone in Teladoc's commitment to clinical excellence and continuous improvement, especially as it helps to advance evaluation standards for evolving models of virtual care. The award strengthens confidence in Teladoc as a trusted healthcare partner across Canada.
TDOC|Teladoc Health Inc|Price:8.911|Chg%:+0.141
This article provides a comprehensive stock analysis of Teladoc Health Inc (TDOC), highlighting its strong fundamentals and significant growth potential, despite being considered fairly valued within its industry. It notes high institutional ownership and a recent "Hold" rating from multiple analysts, with expectations for the stock price to trend upward in the medium term. The report also details the company's business segments, strengths, risks, and its Teladoc Health Inc's score components, including financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment.
